Dataset Information


Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.

ABSTRACT: In cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination.Candidate genes that were expressed differentially between long- and short-term survivors were identified by cDNA microarray analysis of peripheral blood mononuclear cells that were extracted from 30 glioblastoma patients (discovery set) prior to vaccination and validated by quantitative RT-PCR using discovery set and different 23 patients (validation set).SDC-4 mRNA expression levels distinguished between the long- and short-term survivors: 1-year survival rates were 64.0 and 18.5% in SDC4-low and -high patients, respectively.SDC-4 is a novel predictive biomarker for the efficacy of WT1 peptide vaccine.

SUBMITTER: Takashima S 

PROVIDER: S-EPMC5241910 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5600357 | BioStudies
2015-01-01 | S-EPMC4366886 | BioStudies
1000-01-01 | S-EPMC4229357 | BioStudies
1000-01-01 | S-EPMC6296840 | BioStudies
2020-01-01 | S-EPMC7656933 | BioStudies
2020-01-01 | S-EPMC7561406 | BioStudies
2014-01-01 | S-EPMC4229635 | BioStudies
2020-01-01 | S-EPMC7373078 | BioStudies
2020-02-12 | PXD014559 | Pride
2009-01-01 | S-EPMC3631522 | BioStudies